Exclusive Summary

• Best-in-Class potential for a $20 billion market: UB686 is a novel small-molecule NK3R antagonist targeting menopausal vasomotor symptoms (hot flashes), addressing a massive global population of 800 million women.
• Breakthrough superior efficacy: Phase II results demonstrate an 82.3% reduction in hot flash frequency at Week 12, significantly outperforming main competitors like Veozah and Lynkuet.
• Exceptional safety profile and dosing flexibility: It shows zero risk of elevated hepatic enzymes, potentially avoiding FDA black-box warnings for liver monitoring; it also lacks NK1R-related somnolence and supports flexible QD/BID dosing.
• High commercial readiness and license-out value: With successful Phase I/II validation in China and Australia, UB686 is primed to initiate an MRCT Phase III, making it a highly attractive de-risked asset for overseas out-licensing and co-development.

Asset Materials

Contact Us for Full Materials